StockData
Intelligent Bio Solutions Inc. logo

Intelligent Bio Solutions Inc. (INBS) company profile

INBSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends June 30
Số liệu tài chính tới Q4 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3057% below fair value
$1.56+0.06 (+4.00%)

Close on Nov 17, 2026Market cap $4.72MP/E –Yield –

About Intelligent Bio Solutions

Surgical & Medical Instruments & Apparatus, SIC 3841

Intelligent Bio Solutions Inc. is a medical technology company that develops and supplies rapid, non-invasive screening and testing solutions. Its primary offering is the Intelligent Fingerprinting Platform, which features a proprietary drug screening system that analyzes sweat from fingerprints. The system consists of single-use, tamper-evident cartridges and a portable reader unit designed to screen for substances such as opiates, cocaine, methamphetamine, benzodiazepines, cannabis, methadone, and buprenorphine. The company also distributes wearable drug-detection sweat patches. Its customers primarily include organizations in safety-critical sectors, such as construction, manufacturing, engineering, mining, transportation, and logistics, along with judicial bodies and rehabilitation treatment providers.

The company operates globally, with sales predominantly concentrated in the United Kingdom, mainland Europe, and the Middle East, while pursuing distribution across Australia, New Zealand, and North America. It produces cartridges at a manufacturing facility in Cambridge, England, and maintains corporate headquarters in New York City.

Summary of the business section of Intelligent Bio Solutions's latest annual report, written by StockData.

Company profile

Company

Legal name
Intelligent Bio Solutions Inc.
Founded
2016
Headquarters
New York, NY
Address
135 W 41st St,, Floor 5 10036
Phone
(646) 790-5756
Website
ibs.inc
Employees
14, Jun 30, 2025
Industry
Surgical & Medical Instruments & Apparatus
Incorporated in
Delaware
Fiscal year ends
June 30
Auditor
UHY LLP, Melville, NY

Stock & identifiers

Ticker
INBS
Former tickers
GBS until Oct 27, 2022
Exchange
Nasdaq
IPO date
Dec 28, 2020
Shares outstanding
3M, Aug 18, 2026
Public float
$11.71M, Dec 31, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-10 reverse, Dec 16, 2025; 1-for-12 reverse, Jan 29, 2024; 1-for-20 reverse, Feb 10, 2023
SEC CIK
1725430
CUSIP
36151G709
ISIN
US36151G7097
FIGI
BBG004TP0VX9
Share class FIGI
BBG004TP0VY8
LEI
549300JIQ6MVR4PC5311
EIN
82-1512711

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Harry SimeonidisChief Executive Officer34,540
Spiro Kevin SakirisChief Financial Officer35,892
Steven Constantine BoyagesDirector5,031
Jonathan Scott HurdDirector5,006
Jason IsenbergDirector5,000
Nicola Marion FraserDirector5,000

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOtherTotalvs. prior year
Harry Simeonidis
Chief Executive Officer & President
$366.25K$56.95K$59.48K$482.67K+8%
Spiro Sakiris
Chief Financial Officer
$269.02K$49.12K$45.40K$363.53K+8%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Dec 28, 2020
Offer price
$17.00
Securities offered
1,270,589
Gross proceeds
$21.60M
Exchange
Nasdaq
First trading day
Dec 28, 2020
First-day close
$9.58-43.6%
Lock-up ends (est.)
Jun 26, 2021

“Per Unit (2) Total (3) Public offering price $ 17.00 $ 21,600,013 Underwriting discounts (1) $ 1.36 $ 1,728,001 Proceeds to us, before expenses $ 15.64 $ 19,872,011 (1) The underwriters will receive compensation in addition to the underwriting discounts and commissions.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of August 14, 2025, we have 14 full-time employees in Australia and 2 in the United States.”

Corporate history

Events identified from SEC filings

DateEventDetails
Dec 16, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jan 4, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Nov 17, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jul 3, 2023Auditor changeChange in certifying accountant (8-K Item 4.01)
Oct 18, 2022Name changeName changed from GBS Inc. to Intelligent Bio Solutions Inc.
Oct 11, 2022Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Mar 23, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Dec 28, 2020IPOInitial public offering priced (424B4 prospectus)
Dec 22, 2020ListingRegistration of securities on an exchange (Form 8-A)
Sep 19, 2019Name changeName changed from Glucose Biosensor Systems (Greater China) Holdings, Inc. to GBS Inc.

See a number that looks wrong?